Comparison of acute and chronic glucose-lowering effect of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin, in rat models of type 2 diabetes

被引：0
|
作者：
Yoshida, Taishi
Takahashi, Kanako
Nakashima, Ryutaro
Kanda, Shoichi
Okuno, Akira
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A139 / A139
页数：1
相关论文
共 47 条
  • [1] Comparative effects of CS-917, a fructose 1,6-bisphosphatase inhibitor, and metformin
    Okuno, A.
    Yoshida, T.
    Tanaka, J.
    Takahashi, K.
    Kanda, S.
    Nakashima, R.
    Ogawa, J.
    Hagisawa, Y.
    DIABETOLOGIA, 2006, 49 : 132 - 132
  • [2] Initial safety, tolerability and glucose lowering of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes
    Bruce, S. R.
    Walker, J.
    Feins, K.
    Tao, B.
    Triscari, J.
    DIABETOLOGIA, 2006, 49 : 25 - 25
  • [3] Contributions of Hepatic Gluconeogenesis Suppression and Compensative Glycogenolysis on the Glucose-Lowering Effect of CS-917, a Fructose 1,6-Bisphosphatase Inhibitor, in Non-obese Type 2 Diabetes Goto-Kakizaki Rats
    Yoshida, Taishi
    Okuno, Akira
    Takahashi, Kanako
    Ogawa, Junko
    Hagisawa, Yuka
    Kanda, Shoichi
    Fujiwara, Toshihiko
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 (03) : 329 - 335
  • [4] CS-917, a fructose 1,6-bisphosphatase inhibitor, suppresses gluconeogenesis in vitro and in vivo by a different mechanism than metformin
    Okuno, Akira
    Tanaka, Jun
    Takahashi, Kanako
    Nakashima, Ryutaro
    Kanda, Shoichi
    Ogawa, Junko
    Hagisawa, Yuka
    Yoshida, Taishi
    DIABETES, 2006, 55 : A128 - A129
  • [5] MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
    Erion, MD
    van Poelje, PD
    Dang, Q
    Kasibhatla, SR
    Potter, SC
    Reddy, MR
    Reddy, KR
    Jiang, T
    Lipscomb, WN
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (22) : 7970 - 7975
  • [6] CS-917, a fructose 1,6-bisphosphatase inhibitor, has glucose-lowering effects in cynomolgus monkeys and improves postprandial hyperglycemia in goto-kakizaki (GK) rats
    Yoshida, T
    Izumi, M
    Takahashi, K
    Hagisawa, Y
    Ohsumi, J
    Fujiwara, T
    Okuno, A
    DIABETES, 2005, 54 : A116 - A117
  • [7] CS-917, a fructose 1,6-bisphosphatase inhibitor, reduces plasma glucose by suppressing hepatic glucose production, whereas metformin stimulates gastrointestinal glucose uptake
    Okuno, A.
    Tanaka, J.
    Takahashi, K.
    Ogawa, J.
    Hagisawa, Y.
    Kanda, S.
    Yoshida, T.
    DIABETOLOGIA, 2007, 50 : S95 - S95
  • [8] Pharmacokinetics and pharmacodynamics of single-dose CS-917, a novel prodrug of a fructose 1,6-bisphosphatase inhibitor, in patients with type 2 diabetes
    Walker, Joseph R.
    Triscari, Joseph
    Freudenthaler, Stefan
    Golor, George
    Dmuchowski, Carl F.
    Naozumi, Samata
    Kaneko, Tsugio
    Bruce, Simon R.
    DIABETES, 2007, 56 : A551 - A551
  • [9] CS-917, a fructose 1,6-bisphosphatase inhibitor, combined with a thiazolidinedione or insulin decreases plasma glucose and improves lactate metabolism more effectively than CS-917 monotherapy
    Yoshida, T.
    Ogawa, J.
    Hagisawa, Y.
    Kanda, S.
    Takahashi, K.
    Okuno, A.
    DIABETOLOGIA, 2007, 50 : S375 - S375
  • [10] Multiple ascending doses of CS-917, a novel fructose 1,6-bisphosphatase (FBPase) inhibitor, in subjects with type 2 diabetes treated for 14 days
    Triscari, Joseph
    Walker, Joseph
    Feins, Karen
    Tao, Ben
    Bruce, Simon R.
    DIABETES, 2006, 55 : A105 - A106
12345